The core activity of EffRx Pharmaceuticals SA is the development, approval and marketing of medicines for rare and niche diseases in Europe and Switzerland. The company focuses particularly on the late-stage development and market entry of therapeutics for patients with rare diseases such as osteoporosis, adrenal insufficiency, congenital adrenal hyperplasia and Niemann-Pick disease. EffRx works closely with partners to develop and bring new medicines to market, offering accelerated decision-making processes and rapid market entry for its customers.